Home/Pipeline/Technology Platform Development

Technology Platform Development

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Outpace Bio

About Outpace Bio

Outpace Bio is a private, pre-clinical stage biotech pioneering AI-driven protein design to develop next-generation cell therapies for solid tumors. The company's platform creates novel, fully human protein functions to address multiple failure points in current treatments, including immunosuppressive tumor microenvironments, poor T-cell persistence, and lack of specificity. By integrating its modular technology suite (OUTSMART™, OUTLAST™, OUTSPACER™, OUTSAFE™, and logic gating) into cell therapies, Outpace aims to build curative products for a broad range of cancers that are currently untreatable with existing cell therapy approaches.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed